Transcript RA190 - merrus.com

RA190
Small Molecule Proteasome Inhibitor for
Cancer Therapy
Targeting the proteasome…
• Proteasomal degradation of tumor
suppressor proteins is found in many
cancers
• apoptosis arrest
• sustained cell proliferation
• Current
proteasome
inhibitors:
– grave side
effects
– disease
resistance
• RA190:
• Reduced toxicity
• novel mechanism of
action overcomes
drug resistance
• Preferential targeting
of transformed cells
Mechanism Of Action
• Binds to ubiquitin receptor RPN13
• RPN13 is part of the 19S Regulatory Cap
• Responsible for removing Ub from target
proteins
• Proteasome inhibited
• Misfolded protein buildup
The Drug
• Orally available
• Promising toxicity profile
• Works on tumors resistant to bortezumib
• Active against cervical and ovarian cancer, and Multiple
Myeloma
The Business
What we do:
Find cancer cure
Who we are:
CanCure Inc.
“Because we CanCure cancer*!”
* By cancer, we mean cervical and ovarian cancer,
and multiple myeloma.
The Team
• Looking to build a highly dedicated, talented, and
experienced management team:
• Looking for:
• CEO: preferably with product launch experience
• CFO
• CMO
• CRO
• VPs
• Etc…
The Market
• Ovarian cancer: 17th most common cancer
• 21,980 estimated new cases in 2014
• 14,270 deaths
• Cervical cancer: 21st most common cancer
• 12,360 estimated new cases in 2014
• 4,020 deaths
• Multiple myeloma: 14th most common cancer
• 24,050 estimated new cases in 2014
• 11,090 deaths
*From NCI SEER statistics 2014
Financial Projections
1200
1,094.81
Revenue
1000
Profits
875.85
Dollars (Millions)
800
656.89
600
437.93
547.41
400
437.93
218.96
200
0
328.44
218.96
109.48
1
2
3
Years on Market
4
5
Growth Strategy
• Develop companion diagnostic test for RA190
• Explore RA190 in other cancers
Exit Strategy
• Sell company to large pharma